ANDA 214547, held by Norwich. Lisdexamfetamine Dimesylate.
As of Nov 16, 2026, ANDA 214547 (Lisdexamfetamine Dimesylate), held by Norwich, was first approved by FDA on Aug 25, 2023, with 3 approved supplements and 0 published complete response letters.
Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved |
| Lisdexamfetamine Dimesylate10MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 25, 2026 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 25, 2026 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jan 5, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters